Pancreatic Cancer Research

Clinical trialObsCompleted

Predicting Disease Progression and/or Recurrence in Cancer

Tumor Markers, Liquid Biopsies, and Patient Reported Outcomes in Metastatic Colorectal, Pancreas, Biliary, and Esophagogastric Cancers

NCT04776837↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome
Finished, no results posted
Phase
Obs
Status
Completed
Study type
Observational
Start
15 May 2019
Expected end
19 October 2022
Enrollment
159 participants
Sites
1
Primary outcomes
Treatment Response at 1st Scan
Sponsor
Other
Results posted
No
Last update
15 May 2026

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a prospective study addressing the challenge of predicting disease progression and/or recurrence in patients diagnosed with metastatic colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer therapy.

Detailed description public domain (ClinicalTrials.gov)

This research study is evaluating how patient-reported outcomes (e.g. symptoms, quality of life) and biomarkers compare to standard of care clinical assessments such as imaging and tumor markers in predicting the clinical outcomes (e.g. disease progression and survival) in patient populations with colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer therapy Massachusetts General Hospital Cancer Center * Patient reported outcomes will be collected through a series of self-administered questionnaires and blood draws will be used to obtain bio and tumor marker information. * Information will also be collected from the participants electronic medical record. * Tissue may be obtained for next-generation sequencing. * The study will conclude after participants are no longer receiving anti-cancer therapies. * It is expected that about 200 people will take part in this research study

Papers 1

The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.